Related Experiment Video
Updated: Sep 10, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2
M. Galván1, J.P. David, A. Delacourte
1Departamento de Fisiología, Biofísica y Neurociencias, CINVESTAV-IPN, PO Box 14-740, 07000, México, D.F., México.
Abstract:
In the present study, neurons of the entorhinal cortex, hippocampus and frontal lobe from non-demented and Alzheimer's disease (AD) cases, were stained in order to study neurofibrillary changes. We have used double immunolabeling with a phosphorylation dependent monoclonal antibody (mAb) to tau, AD2, and the histochemical dye thiazin red (TR). MAb AD2 specifically recognizes phosphorylated Ser396 and Ser404, while TR shows binding sites for amyloid-beta$ and tau when they are in fibrillar states. We show a morphological sequence of changes in the development of neurofibrillary tangles (NFTs), starting from mAb AD2 diffuse labeling in non-NFT bearing cells recognized by mAb AD2, then going through two subtypes of intracellular NFTs, to a final stage as extracellular-NFTs. Morphometric analysis of the density of AD2 immunoreactive structures showed the NFT density in hippocampus and frontal lobe were the best parameters to differentiate normal aging from AD. Densities of AD2 immunoreactive structures in hippocampus and frontal lobe correlated with the Clinical Dementing Rating score. Based upon the variety of appearances of immunoreactivity displayed by mAb AD2, we were able to stage neurofibrillary changes at the level of individual neurons and brain areas. Our results demonstrate that the intensity of neurofibrillary changes in the hippocampus as well as the extent of the degeneration process in association areas differentiate normal aging from AD, and are well correlated with cognitive impairment.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction

